Symbols / REVB $1.18 -5.61% Revelation Biosciences, Inc.
REVB Chart
About
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.39M |
| Enterprise Value | -5.36M | Income | -14.87M | Sales | — |
| Book/sh | 5.59 | Cash/sh | 2.89 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -0.36 | PEG | — |
| P/S | — | P/B | 0.21 | P/C | — |
| EV/EBITDA | 0.59 | EV/Sales | — | Quick Ratio | 5.38 |
| Current Ratio | 5.41 | Debt/Eq | 8.43 | LT Debt/Eq | — |
| EPS (ttm) | -23.95 | EPS next Y | -3.29 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-07 | ROA | -62.28% |
| ROE | -131.38% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 3.72M |
| Shs Float | 3.27M | Short Float | 0.75% | Short Ratio | 0.27 |
| Short Interest | — | 52W High | 44.77 | 52W Low | 1.06 |
| Beta | -0.17 | Avg Volume | 673.69K | Volume | 80.32K |
| Target Price | $19.25 | Recom | Strong_buy | Prev Close | $1.25 |
| Price | $1.18 | Change | -5.61% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
- Kidney injury trial draws 5 specialists to guide Revelation study - Stock Titan Mon, 06 Apr 2026 13
- REVB Stock Drops 10% After Company Announces Third Reverse Split In A Year - Stocktwits Wed, 28 Jan 2026 08
- Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours? - Benzinga Fri, 23 Jan 2026 08
- Revelation Biosciences (REVB) stock ticks up premarket after FDA lays out Gemini trial path - ts2.tech Fri, 23 Jan 2026 08
- REVB SEC Filings - Revelation Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan hu, 02 Apr 2026 02
- Revelation Biosciences to implement 1-for-4 reverse stock split - Investing.com Mon, 26 Jan 2026 08
- Revelation Biosciences (REVB) price target decreased by 37.65% to 54.06 - MSN Sat, 28 Mar 2026 10
- Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds - newswire.com Fri, 23 Jan 2026 08
- If You Invested $1,000 in Revelation Biosciences (REVB) - Stock Titan Mon, 23 Mar 2026 05
- Revelation Biosciences reaches FDA agreement on AKI treatment pathway - Investing.com Wed, 21 Jan 2026 08
- Revelation Biosciences Stock Slides 17% After Company Reports 3 Severe Adverse Events In Early Stage Trial Of Inflammation Drug - Stocktwits ue, 09 Sep 2025 07
- Kidney drug Gemini advances at Revelation, cash runway into 2027 - Stock Titan hu, 26 Feb 2026 08
- Revelation Biosciences' Roth fireside chat streams live at 2 p.m. PT - Stock Titan ue, 24 Mar 2026 07
- Revelation Biosciences trades new 5-year warrants for $11M cash - Stock Titan Fri, 23 Jan 2026 08
- A single Gemini dose restored immune response for 7 days in CKD study - Stock Titan Mon, 30 Mar 2026 13
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
9.07
+13.74%
|
7.98
-7.87%
|
8.66
-20.32%
|
10.86
|
| Research And Development |
|
4.06
+14.51%
|
3.55
-14.40%
|
4.15
-22.90%
|
5.38
|
| Selling General And Administration |
|
5.01
+13.12%
|
4.43
-1.88%
|
4.51
-17.79%
|
5.49
|
| General And Administrative Expense |
|
5.01
+13.12%
|
4.43
-1.88%
|
4.51
-17.79%
|
5.49
|
| Salaries And Wages |
|
3.05
+10.02%
|
2.77
+21.86%
|
2.27
+21.19%
|
1.87
|
| Other Gand A |
|
1.96
+18.31%
|
1.66
-25.96%
|
2.24
-38.03%
|
3.61
|
| Total Expenses |
|
9.07
+13.74%
|
7.98
-7.87%
|
8.66
-20.32%
|
10.86
|
| Operating Income |
|
-9.07
-13.74%
|
-7.98
+7.87%
|
-8.66
+20.32%
|
-10.86
|
| Total Operating Income As Reported |
|
-9.07
-13.74%
|
-7.98
+7.87%
|
-8.66
+20.32%
|
-10.86
|
| EBITDA |
|
-9.04
-13.80%
|
-7.95
+7.93%
|
-8.63
+20.37%
|
-10.84
|
| Normalized EBITDA |
|
-9.05
-12.67%
|
-8.03
+52.66%
|
-16.96
-56.47%
|
-10.84
|
| Reconciled Depreciation |
|
0.03
-3.10%
|
0.03
+11.47%
|
0.03
+0.00%
|
0.03
|
| EBIT |
|
-9.07
-13.74%
|
-7.98
+7.87%
|
-8.66
+20.32%
|
-10.86
|
| Total Unusual Items |
|
0.00
-97.35%
|
0.08
-99.02%
|
8.33
|
—
|
| Total Unusual Items Excluding Goodwill |
|
0.00
-97.35%
|
0.08
-99.02%
|
8.33
|
—
|
| Net Income |
|
-8.91
+40.73%
|
-15.04
-12405.64%
|
-0.12
+98.89%
|
-10.83
|
| Pretax Income |
|
-8.91
+40.73%
|
-15.04
-12405.64%
|
-0.12
+98.89%
|
-10.83
|
| Other Income Expense |
|
0.16
+102.23%
|
-7.06
-182.74%
|
8.54
+24316.25%
|
0.03
|
| Other Non Operating Income Expenses |
|
0.16
+102.17%
|
-7.14
-3543.76%
|
0.21
+493.42%
|
0.03
|
| Gain On Sale Of Security |
|
0.00
-97.35%
|
0.08
-99.02%
|
8.33
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-8.91
+40.73%
|
-15.04
-12405.64%
|
-0.12
+98.89%
|
-10.83
|
| Net Income From Continuing Operation Net Minority Interest |
|
-8.91
+40.73%
|
-15.04
-12405.64%
|
-0.12
+98.89%
|
-10.83
|
| Net Income From Continuing And Discontinued Operation |
|
-8.91
+40.73%
|
-15.04
-12405.64%
|
-0.12
+98.89%
|
-10.83
|
| Net Income Continuous Operations |
|
-8.91
+40.73%
|
-15.04
-12405.64%
|
-0.12
+98.89%
|
-10.83
|
| Normalized Income |
|
-8.92
+41.03%
|
-15.12
-78.95%
|
-8.45
+21.98%
|
-10.83
|
| Net Income Common Stockholders |
|
-14.87
+1.15%
|
-15.04
-12405.64%
|
-0.12
+98.89%
|
-10.83
|
| Otherunder Preferred Stock Dividend |
|
5.95
|
0.00
|
—
|
—
|
| Diluted EPS |
|
-23.95
+97.72%
|
-1,052.16
-938.86%
|
-101.28
+99.89%
|
-91,775.84
|
| Basic EPS |
|
-23.95
+97.72%
|
-1,052.16
-938.86%
|
-101.28
+99.89%
|
-91,775.84
|
| Basic Average Shares |
|
0.62
+4243.58%
|
0.01
+1104.04%
|
0.00
+905.93%
|
0.00
|
| Diluted Average Shares |
|
0.62
+4243.58%
|
0.01
+1104.04%
|
0.00
+905.93%
|
0.00
|
| Diluted NI Availto Com Stockholders |
|
-14.87
+1.15%
|
-15.04
-12405.64%
|
-0.12
+98.89%
|
-10.83
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
11.58
+74.91%
|
6.62
-45.78%
|
12.21
+121.91%
|
5.50
|
| Current Assets |
|
10.81
+64.67%
|
6.57
-45.95%
|
12.15
+124.40%
|
5.41
|
| Cash Cash Equivalents And Short Term Investments |
|
10.70
+64.65%
|
6.50
-45.80%
|
11.99
+128.28%
|
5.25
|
| Cash And Cash Equivalents |
|
10.70
+64.65%
|
6.50
-45.80%
|
11.99
+128.28%
|
5.25
|
| Prepaid Assets |
|
0.08
+349.76%
|
0.02
-68.85%
|
0.06
|
0.00
|
| Current Deferred Assets |
|
—
|
0.00
-100.00%
|
0.07
-18.40%
|
0.09
|
| Other Current Assets |
|
0.03
-31.42%
|
0.05
+67.94%
|
0.03
-59.69%
|
0.07
|
| Total Non Current Assets |
|
0.77
+1269.20%
|
0.06
-13.45%
|
0.07
-27.79%
|
0.09
|
| Net PPE |
|
0.74
+1214.27%
|
0.06
-13.45%
|
0.07
-27.79%
|
0.09
|
| Gross PPE |
|
0.84
+455.36%
|
0.15
+14.53%
|
0.13
+0.00%
|
0.13
|
| Accumulated Depreciation |
|
-0.10
-4.42%
|
-0.09
-41.75%
|
-0.07
-59.88%
|
-0.04
|
| Other Properties |
|
0.84
+455.36%
|
0.15
+14.53%
|
0.13
+0.00%
|
0.13
|
| Other Non Current Assets |
|
0.03
|
—
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
2.72
+42.24%
|
1.91
-65.61%
|
5.56
+25.03%
|
4.45
|
| Current Liabilities |
|
2.00
+4.42%
|
1.91
-65.61%
|
5.56
+25.03%
|
4.45
|
| Payables And Accrued Expenses |
|
1.98
+3.21%
|
1.91
-23.83%
|
2.51
+63.17%
|
1.54
|
| Payables |
|
0.58
-26.30%
|
0.78
-42.38%
|
1.36
+145.38%
|
0.55
|
| Accounts Payable |
|
0.58
-26.30%
|
0.78
-42.38%
|
1.36
+145.38%
|
0.55
|
| Current Accrued Expenses |
|
1.40
+23.68%
|
1.13
-1.94%
|
1.15
+16.94%
|
0.99
|
| Current Debt And Capital Lease Obligation |
|
0.02
|
—
|
—
|
—
|
| Current Capital Lease Obligation |
|
0.02
|
0.00
|
—
|
0.00
|
| Current Deferred Liabilities |
|
—
|
0.00
-100.00%
|
2.91
+0.00%
|
2.91
|
| Other Current Liabilities |
|
—
|
0.00
-98.41%
|
0.14
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.72
|
0.00
|
0.00
|
0.00
|
| Long Term Debt And Capital Lease Obligation |
|
0.72
|
0.00
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
0.72
|
0.00
|
—
|
—
|
| Stockholders Equity |
|
8.86
+88.20%
|
4.71
-29.17%
|
6.65
+531.64%
|
1.05
|
| Common Stock Equity |
|
8.86
+88.20%
|
4.71
-29.17%
|
6.65
+531.64%
|
1.05
|
| Capital Stock |
|
0.00
+3500.00%
|
0.00
+175.00%
|
0.00
-79.22%
|
0.00
|
| Common Stock |
|
0.00
+3500.00%
|
0.00
+175.00%
|
0.00
-79.22%
|
0.00
|
| Preferred Stock |
|
—
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
1.58
+3539.80%
|
0.04
+3060.35%
|
0.00
+1066.95%
|
0.00
|
| Ordinary Shares Number |
|
1.58
+3539.80%
|
0.04
+3060.35%
|
0.00
+1066.95%
|
0.00
|
| Additional Paid In Capital |
|
58.28
+28.90%
|
45.21
+40.79%
|
32.11
+21.65%
|
26.40
|
| Retained Earnings |
|
-49.42
-22.01%
|
-40.51
-59.05%
|
-25.47
-0.47%
|
-25.35
|
| Total Equity Gross Minority Interest |
|
8.86
+88.20%
|
4.71
-29.17%
|
6.65
+531.64%
|
1.05
|
| Total Capitalization |
|
8.86
+88.20%
|
4.71
-29.17%
|
6.65
+531.64%
|
1.05
|
| Working Capital |
|
8.81
+89.45%
|
4.65
-29.33%
|
6.58
+584.04%
|
0.96
|
| Invested Capital |
|
8.86
+88.20%
|
4.71
-29.17%
|
6.65
+531.64%
|
1.05
|
| Total Debt |
|
0.75
|
0.00
|
—
|
0.00
|
| Capital Lease Obligations |
|
0.75
|
0.00
|
—
|
0.00
|
| Net Tangible Assets |
|
8.86
+88.20%
|
4.71
-29.17%
|
6.65
+531.64%
|
1.05
|
| Tangible Book Value |
|
8.86
+88.20%
|
4.71
-29.17%
|
6.65
+531.64%
|
1.05
|
| Preferred Stock Equity |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-8.27
+54.86%
|
-18.32
-151.45%
|
-7.29
+35.06%
|
-11.22
|
| Cash Flow From Continuing Operating Activities |
|
-8.27
+54.86%
|
-18.32
-151.45%
|
-7.29
+35.06%
|
-11.22
|
| Net Income From Continuing Operations |
|
-8.91
+40.73%
|
-15.04
-12405.64%
|
-0.12
+98.89%
|
-10.83
|
| Depreciation Amortization Depletion |
|
0.03
-3.10%
|
0.03
+11.47%
|
0.03
+0.00%
|
0.03
|
| Depreciation |
|
0.03
-3.10%
|
0.03
+11.47%
|
0.03
+0.00%
|
0.03
|
| Depreciation And Amortization |
|
0.03
-3.10%
|
0.03
+11.47%
|
0.03
+0.00%
|
0.03
|
| Other Non Cash Items |
|
0.02
-25.48%
|
0.03
|
—
|
0.01
|
| Stock Based Compensation |
|
0.60
+252.60%
|
0.17
+8.43%
|
0.16
-48.29%
|
0.30
|
| Operating Gains Losses |
|
0.01
+111.11%
|
-0.08
+99.02%
|
-8.33
|
—
|
| Gain Loss On Investment Securities |
|
-0.00
+97.35%
|
-0.08
+99.02%
|
-8.33
|
—
|
| Gain Loss On Sale Of PPE |
|
0.01
|
0.00
|
—
|
—
|
| Change In Working Capital |
|
-0.01
+99.82%
|
-3.42
-448.53%
|
0.98
+234.36%
|
-0.73
|
| Change In Prepaid Assets |
|
-0.04
-347.88%
|
0.02
+255.65%
|
-0.01
-102.03%
|
0.57
|
| Change In Payables And Accrued Expense |
|
0.06
+101.81%
|
-3.51
-485.27%
|
0.91
+174.59%
|
-1.22
|
| Change In Accrued Expense |
|
0.27
+109.19%
|
-2.94
-1912.71%
|
0.16
+129.13%
|
-0.56
|
| Change In Payable |
|
-0.21
+64.23%
|
-0.58
-176.87%
|
0.75
+212.55%
|
-0.67
|
| Change In Account Payable |
|
-0.21
+64.23%
|
-0.58
-176.87%
|
0.75
+212.55%
|
-0.67
|
| Change In Other Working Capital |
|
—
|
0.07
-13.33%
|
0.08
+234.20%
|
-0.06
|
| Change In Other Current Assets |
|
-0.03
|
0.00
|
—
|
—
|
| Change In Other Current Liabilities |
|
0.01
|
0.00
|
0.00
+100.00%
|
-0.02
|
| Investing Cash Flow |
|
0.00
+100.00%
|
-0.02
|
0.00
|
0.00
|
| Cash Flow From Continuing Investing Activities |
|
0.00
+100.00%
|
-0.02
|
0.00
|
0.00
|
| Net PPE Purchase And Sale |
|
0.00
+100.00%
|
-0.02
|
0.00
|
0.00
|
| Purchase Of PPE |
|
0.00
+100.00%
|
-0.02
|
0.00
|
0.00
|
| Capital Expenditure |
|
—
|
-0.02
|
—
|
—
|
| Financing Cash Flow |
|
12.47
-2.93%
|
12.85
-8.39%
|
14.03
-7.72%
|
15.20
|
| Cash Flow From Continuing Financing Activities |
|
12.47
-2.93%
|
12.85
-8.39%
|
14.03
-7.72%
|
15.20
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-0.80
|
| Issuance Of Debt |
|
—
|
—
|
0.00
-100.00%
|
2.50
|
| Repayment Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-3.30
|
| Short Term Debt Issuance |
|
—
|
—
|
0.00
-100.00%
|
2.50
|
| Short Term Debt Payments |
|
—
|
—
|
0.00
+100.00%
|
-3.30
|
| Net Short Term Debt Issuance |
|
—
|
—
|
0.00
+100.00%
|
-0.80
|
| Net Common Stock Issuance |
|
3.39
-37.45%
|
5.42
-61.39%
|
14.03
+215.21%
|
4.45
|
| Repurchase Of Capital Stock |
|
—
|
0.00
+100.00%
|
-0.01
|
—
|
| Proceeds From Stock Option Exercised |
|
9.08
+22.23%
|
7.43
+21854932.35%
|
0.00
-99.33%
|
0.01
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
11.53
|
| Changes In Cash |
|
4.20
+176.49%
|
-5.49
-181.51%
|
6.74
+69.39%
|
3.98
|
| Beginning Cash Position |
|
6.50
-45.80%
|
11.99
+128.28%
|
5.25
+312.09%
|
1.27
|
| End Cash Position |
|
10.70
+64.65%
|
6.50
-45.80%
|
11.99
+128.28%
|
5.25
|
| Free Cash Flow |
|
-8.27
+54.91%
|
-18.34
-151.71%
|
-7.29
+35.06%
|
-11.22
|
| Change In Interest Payable |
|
—
|
—
|
0.00
-100.00%
|
0.04
|
| Common Stock Issuance |
|
3.39
-37.45%
|
5.42
-61.39%
|
14.03
+215.21%
|
4.45
|
| Issuance Of Capital Stock |
|
3.39
-37.45%
|
5.42
-61.39%
|
14.03
+214.85%
|
4.46
|
| Net Preferred Stock Issuance |
|
—
|
0.00
+100.00%
|
-0.01
-200.00%
|
0.01
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.01
|
| Preferred Stock Payments |
|
—
|
0.00
+100.00%
|
-0.01
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-19 View
- 8-K2026-02-26 View
- 10-K2026-02-26 View
- 42026-02-05 View
- 42026-02-05 View
- 42026-02-05 View
- 42026-02-05 View
- 42026-02-05 View
- 8-K2026-01-29 View
- 8-K2026-01-22 View
- 42026-01-12 View
- 42026-01-12 View
- 42026-01-12 View
- 42026-01-12 View
- 42026-01-12 View
- 8-K2025-12-03 View
- 8-K2025-11-06 View
- 10-Q2025-11-06 View
- 42025-10-31 View
- 42025-10-31 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|